Comparative Pharmacology
Head-to-head clinical analysis: PERCODAN DEMI versus TALWIN COMPOUND.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PERCODAN DEMI versus TALWIN COMPOUND.
PERCODAN-DEMI vs TALWIN COMPOUND
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxycodone is a full mu-opioid receptor agonist; aspirin inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.
TALWIN COMPOUND contains pentazocine, a mixed agonist-antagonist at opioid receptors with partial agonist activity at mu receptors and full agonist activity at kappa receptors, and naloxone, an opioid antagonist that reduces abuse potential by precipitating withdrawal in opioid-dependent individuals when injected. The combination provides analgesia through pentazocine's central and peripheral opioid receptor activation, while naloxone is not absorbed orally but prevents intravenous abuse.
1 tablet (oxycodone 2.25 mg/aspirin 325 mg) orally every 6 hours as needed for pain; maximum 4 tablets in 24 hours.
1-2 tablets (each tablet contains pentazocine HCl 12.5 mg and aspirin 325 mg) orally every 3-4 hours as needed, not to exceed 6 tablets per day.
None Documented
None Documented
Oxycodone: 3-4 hours; salicylate (aspirin): 2-3 hours at low doses, 15-30 hours at high doses; terminal half-life clinically relevant for dosing interval (q4-6h).
Pentazocine: 2-3 hours; naloxone: 1-1.5 hours. Clinical context: Repeated dosing may prolong effective half-life due to tissue accumulation.
Renal: ~90% (oxycodone: ~60% as metabolites, ~10% unchanged; aspirin: ~80% as salicylates, ~10% unchanged). Biliary/fecal: minor.
Renal: 60-70% as unchanged drug and metabolites; biliary/fecal: 20-30% as conjugates.
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination